Beacon Investment Advisory Services Inc. Has $37.84 Million Stock Position in Insulet Co. (NASDAQ:PODD)

Beacon Investment Advisory Services Inc. decreased its holdings in Insulet Co. (NASDAQ:PODD - Free Report) by 2.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 162,584 shares of the medical instruments supplier's stock after selling 3,972 shares during the quarter. Insulet accounts for about 1.6% of Beacon Investment Advisory Services Inc.'s portfolio, making the stock its 19th largest holding. Beacon Investment Advisory Services Inc. owned approximately 0.23% of Insulet worth $37,841,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. increased its position in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 58 shares during the period. International Assets Investment Management LLC bought a new position in Insulet in the 2nd quarter valued at about $32,000. Venturi Wealth Management LLC raised its position in shares of Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after buying an additional 133 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Insulet by 81.0% during the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock worth $37,000 after acquiring an additional 81 shares during the period. Finally, CVA Family Office LLC boosted its position in shares of Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier's stock worth $50,000 after acquiring an additional 145 shares in the last quarter.

Insulet Trading Down 0.1 %

Insulet stock traded down $0.29 during mid-day trading on Monday, hitting $266.49. 609,741 shares of the stock were exchanged, compared to its average volume of 770,058. The firm's fifty day simple moving average is $244.40 and its two-hundred day simple moving average is $214.37. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.40. The stock has a market capitalization of $18.69 billion, a price-to-earnings ratio of 45.68, a PEG ratio of 4.08 and a beta of 1.22.

Wall Street Analysts Forecast Growth

PODD has been the subject of a number of research analyst reports. Piper Sandler boosted their price target on Insulet from $230.00 to $285.00 and gave the stock an "overweight" rating in a report on Tuesday, September 17th. Barclays increased their target price on shares of Insulet from $220.00 to $234.00 and gave the stock an "equal weight" rating in a report on Monday, November 11th. UBS Group lifted their price target on shares of Insulet from $211.00 to $223.00 and gave the company a "neutral" rating in a report on Friday, August 9th. Canaccord Genuity Group upped their price objective on shares of Insulet from $236.00 to $269.00 and gave the stock a "buy" rating in a research report on Wednesday, September 25th. Finally, Citigroup raised their target price on shares of Insulet from $250.00 to $275.00 and gave the company a "buy" rating in a research report on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Insulet currently has an average rating of "Moderate Buy" and a consensus price target of $253.27.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.